iBio (IBIO) Institutional Ownership : 15.66% (As of Jul. 05, 2025)

View and export this data going back to 2008. Start your Free Trial

What is iBio Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, iBio's institutional ownership is 15.66%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, iBio's Insider Ownership is 48.81%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, iBio's Float Percentage Of Total Shares Outstanding is 99.92%.

iBio Institutional Ownership Historical Data

The historical data trend for iBio's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

iBio Institutional Ownership Chart

iBio Historical Data

The historical data trend for iBio can be seen below:

	2024-09-30	2024-10-31	2024-11-30	2024-12-31	2025-01-31	2025-02-28	2025-03-31	2025-04-30	2025-05-31	2025-06-30
Institutional Ownership	3.14	3.92	1.38	1.48	1.37	1.34	2.12	2.14	2.30	1.30

iBio Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

iBio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » iBio Inc (NAS:IBIO) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

0JV0:Germany

Address

11750 Sorrento Valley Road, Suite 200, San Diego, CA, USA, 92121

Website

https://www.ibioinc.com

iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.

Executives

Gary Sender	director	C/O SYNERGY PHARMACEUTICALS INC., 420 LEXINGTON AVE, NEW YORK NY 10020
Felipe Duran	officer: Interim CFO	8800 HSC PARKWAY, BRYAN TX 77807
William D Clark	director	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
Martin Brenner	officer: Chief Scientific Officer	C/O PFENEX INC., 10790 ROSELLE STREET, SAN DIEGO CA 92121
Evert B. Schimmelpennink	director	C/O PFENEX INC., 10790 ROSELLE STREET, SAN DIEGO CA 92121
Isett Thomas Francis 3rd	director, officer: CEO and Executive Chairman	C/O IBIO INC. 600 MADISON AVENUE, SUITE 1601, NEW YORK NY 10022
Robert Matthew Lutz	officer: See Remarks	900 NORTHBROOK DRIVE, SUITE 200, TREVOSE PA 19053
Randy Joe Maddux	officer: Chief Operating Officer	2401 4TH AVENUE, SUITE #1050, SEATTLE WA 98121
Alexandra Kropotova	director	RIVER OAKS TOWER, 8800 HSC PARKWAY, BYRAN TX 77807
Linda Washington Armstrong	director	8800 HSC PARKWAY, BRYAN TX 77807
John Delta	officer: Principal Accounting Officer	8800 HSC PARKWAY, BRYAN TX 77807
Eastern Capital Ltd	10 percent owner	10 MARKET STREET, #773, CAMANA BAY, GRAND CAYMAN E9 KY1-9006
Robert L Erwin	officer: President	C/O IBIO, INC., 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711
James P. Mullaney	officer: Chief Financial Officer	C/O IBIO, INC., 600 MADISON AVE., SUITE 1601, NEW YORK NY 10022
Carl Desantis	10 percent owner	C/O CDS INTERNATIONAL HOLDINGS, 3299 NW SECOND AVE, BOCA RATON FL 33431